Zentalis Pharmaceuticals (NASDAQ:ZNTL) Shares Up 7.1%

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTLGet Free Report) shot up 7.1% during mid-day trading on Wednesday . The company traded as high as $15.56 and last traded at $15.45. 196,029 shares changed hands during trading, a decline of 76% from the average session volume of 815,789 shares. The stock had previously closed at $14.43.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on ZNTL. HC Wainwright reaffirmed a “buy” rating and issued a $46.00 price target on shares of Zentalis Pharmaceuticals in a research note on Wednesday, February 28th. Wedbush lifted their price objective on Zentalis Pharmaceuticals from $12.00 to $15.00 and gave the stock a “neutral” rating in a research note on Wednesday, February 28th. Three research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $38.57.

Read Our Latest Stock Report on ZNTL

Zentalis Pharmaceuticals Trading Up 8.2 %

The stock has a 50-day moving average price of $13.58 and a two-hundred day moving average price of $14.67. The stock has a market cap of $1.11 billion, a price-to-earnings ratio of -3.39 and a beta of 1.73.

Zentalis Pharmaceuticals (NASDAQ:ZNTLGet Free Report) last released its quarterly earnings data on Tuesday, February 27th. The company reported ($0.83) EPS for the quarter, beating analysts’ consensus estimates of ($0.92) by $0.09. Research analysts predict that Zentalis Pharmaceuticals, Inc. will post -3.72 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Zentalis Pharmaceuticals news, CFO Melissa B. Epperly sold 2,573 shares of the company’s stock in a transaction that occurred on Monday, February 12th. The stock was sold at an average price of $11.44, for a total value of $29,435.12. Following the transaction, the chief financial officer now directly owns 451,449 shares of the company’s stock, valued at approximately $5,164,576.56. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. 6.10% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the company. US Bancorp DE lifted its position in shares of Zentalis Pharmaceuticals by 88.7% in the 2nd quarter. US Bancorp DE now owns 887 shares of the company’s stock worth $25,000 after acquiring an additional 417 shares during the period. Captrust Financial Advisors increased its stake in shares of Zentalis Pharmaceuticals by 15,160.0% in the 1st quarter. Captrust Financial Advisors now owns 763 shares of the company’s stock valued at $35,000 after buying an additional 758 shares during the period. China Universal Asset Management Co. Ltd. increased its stake in shares of Zentalis Pharmaceuticals by 132.2% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 1,809 shares of the company’s stock valued at $36,000 after buying an additional 1,030 shares during the period. Quest Partners LLC bought a new stake in Zentalis Pharmaceuticals in the fourth quarter valued at about $38,000. Finally, Tower Research Capital LLC TRC grew its stake in Zentalis Pharmaceuticals by 252.3% in the fourth quarter. Tower Research Capital LLC TRC now owns 3,615 shares of the company’s stock valued at $55,000 after acquiring an additional 2,589 shares during the period.

About Zentalis Pharmaceuticals

(Get Free Report)

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.

Featured Articles

Receive News & Ratings for Zentalis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zentalis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.